Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma. Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, et al. Blood 2023 Feb 23:blood.2022018598. doi: 10.1182/blood.2022018598.

Read + Share

Amedeo Smart

Independent Medical Education

Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, et al. Dual targeting of CD19 and CD22 with Bicistronic CAR-T cells in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood 2023 Feb 23:blood.2022018598. doi: 10.1182/blood.2022018598.
PMID: 36821767